Dados B3 › ARTR3 × VAMO3
ARTR3 × VAMO3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | ARTR3 | VAMO3 | year |
|---|---|---|---|
| ROE | 5.9% | 0.0% | 2025 |
| ROIC | 11.6% | 13.8% | 2025 |
| ROA | 1.0% | 1.5% | 2025 |
| Gross margin | 23.0% | 52.4% | 2025 |
| EBIT margin | 32.0% | 45.4% | 2025 |
| Net margin | 3.8% | 5.7% | 2025 |
| Net debt/EBITDA | 3.33x | 3.28x | 2025 |
| Current ratio | 0.99x | 1.81x | 2025 |
| Revenue growth (1y) | -13.3% | 22.5% | 2025 |
| Revenue growth (5y CAGR) | 9.6% | 30.6% | 2025 |
| Piotroski F-Score | 6/9 | 5/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | ARTR3 | VAMO3 | year |
|---|---|---|---|
| P/E | 22.53x | — | 2015 × 2025 |
| P/B | 1.50x | 1.55x | 2015 × 2025 |
| EV/EBITDA | 7.24x | 4.37x | 2015 × 2025 |
| FCF yield | -35.4% | -23.1% | 2015 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 15:40 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.